Understanding how certain immune cells contribute to lung problems caused by schistosomiasis.
Official title: The contribution of hypoxia inducible factor-1-dependent glycolysis in lung interstitial macrophages to the pathobiology of schistosomiasis-induced pulmonary hypertension.
Funded at University of California, San Francisco · NIH-11046623 · Data updated 2026-11-12
This study is looking at how a specific protein in immune cells affects their energy use and may contribute to lung problems caused by schistosomiasis, with the goal of finding new ways to help treat this condition.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | April 5, 2023 |
| Project end | March 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $169,020 |
| NIH project number | 5K08HL168310-03 |
| Project ID | NIH-11046623 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with schistosomiasis or those experiencing pulmonary hypertension related to this condition.
✕Less likely to help
Patients with pulmonary hypertension not related to schistosomiasis may not benefit from this research.
What this research studies
This research investigates the role of a specific transcription factor, hypoxia inducible factor-1 (HIF-1), and its influence on glycolysis in lung interstitial macrophages, which are immune cells involved in schistosomiasis-induced pulmonary hypertension (Sch-PH). The study aims to uncover how HIF-1-dependent glycolysis may promote the development of Sch-PH by examining changes in these immune cells in both human and mouse models. By analyzing the behavior of these macrophages and their metabolic processes, the research seeks to identify potential therapeutic targets for treating this neglected tropical disease.
Why it matters
Potential benefit: If successful, this research could lead to new treatments for patients suffering from schistosomiasis-induced pulmonary hypertension.
How similar studies have gone: Previous research has shown promising results in understanding the role of metabolic pathways in other forms of pulmonary hypertension, suggesting potential for success in this novel approach.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Lee, Michael Hyunjean — University of California, San Francisco
- Study coordinator: Lee, Michael Hyunjean
Related research
Other NIH-funded projects on the same topics.
-
FGF signaling and vascular remodeling in lung hypertension
A doctor-scientist at Washington University is studying how fibroblast growth factor (FGF) signaling affects pulmonary hypertension and exploring new potential therapies.
-
Investigating how a specific enzyme contributes to lung disease caused by low oxygen levels.
This study is looking at how a specific enzyme affects lung cells in people with pulmonary arterial hypertension (PAH), which is a serious lung condition, to find new ways to help treat it.
-
Understanding how low oxygen levels during pregnancy affect newborn lung health
This study is looking at how not getting enough oxygen in the womb might cause high blood pressure in the lungs of newborns, and it aims to understand how a certain part of the lungs works to help with blood flow, which could lead to better treatments for babies who are affected.
-
Investigating how fibroblast growth factor signaling can protect against pulmonary hypertension caused by low oxygen levels
This study is looking at how a special protein called FGF can help protect blood vessels in people with pulmonary hypertension from damage caused by low oxygen, with the hope of finding new treatments that could improve your health.
-
Understanding how certain immune cells contribute to high blood pressure in the lungs caused by low oxygen levels.
This study is looking at how certain immune cells in your body might affect high blood pressure in the lungs caused by low oxygen levels, with the hope of finding new ways to help people who have this condition.
-
Understanding how CD4 T cells fuel schistosomiasis-related lung disease
A study explores how specific immune cells and inflammatory signals in schistosomiasis may contribute to pulmonary hypertension in people affected by the disease.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.